Role of the IRS-1 and/or -2 in the pathogenesis of insulin resistance in Dahl salt-sensitive (S) rats

Marlene F. Shehata
Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

Abstract

Insulin resistance is a common finding in hypertensive humans and animal models. The Dahl salt-sensitive (S) rat is an ideal model of genetically predetermined insulin resistance and salt-sensitive hypertension. Along the insulin signaling pathway, the insulin receptor substrates 1 and 2 (IRS-1 and -2) are important mediators of insulin signaling. IRS-1 and/or IRS-2 genetic variant(s) and/or enhanced serine phosphorylation correlate with insulin resistance. The present commentary was designed to highlight the significance of IRS-1 and/or -2 in the pathogenesis of insulin resistance. An emphasis will be given to the putative role of IRS-1 and/or -2 genetic variant(s) and serine phosphorylation in precipitating insulin resistance.

Insulin resistance is at the crossroads of the cardiometabolic syndrome

Insulin resistance is a disorder characterized by the improper utilization of glucose by the cells. This is because of an existing and/or acquired impairment of the cell's ability to respond to exogenous or endogenous insulin. This, in turn, results in β-cell compensation failure and excessive blood glucose levels in the midst of hyperinsulinemia.1 Insulin resistance is a disorder characterized by the improper utilization of glucose by the cells. This is because of an existing and/or acquired impairment of the cell's ability to respond to exogenous or endogenous insulin. This, in turn, results in β-cell compensation failure and excessive blood glucose levels in the midst of hyperinsulinemia.1 Insulin resistance is a disorder characterized by the improper utilization of glucose by the cells. This is because of an existing and/or acquired impairment of the cell's ability to respond to exogenous or endogenous insulin. This, in turn, results in β-cell compensation failure and excessive blood glucose levels in the midst of hyperinsulinemia.1 Insulin resistance is at the crossroads of the cardiometabolic syndrome.

Insulin resistance in Dahl S rats

Dahl S rats represent an ideal model of insulin resistance syndrome because of its genetically predetermined insulin resistance,11,12 hypertriglyceridemia, abdominal obesity, and salt-sensitive hypertension.11 Regarding insulin concentrations, Dahl rats in general have higher values for insulin concentration than control Sprague Dawley rats implying their increased genetic susceptibility to insulin resistance.11 Additionally, Dahl S rats have an increased serum insulin response to an oral glucose load independent of different salt intakes compared to Dahl salt-resistant (R) rats.15 Regarding insulin sensitivity, Dahl S rats have decreased sensitivity to insulin,14 as evidenced by a decreased insulin-stimulated glucose uptake by skeletal muscles obtained from Dahl S vs. Dahl salt-resistant (R) rats.14 Regarding insulin receptors, distribution, number, and affinity, they were all comparable in skeletal muscle and kidney of Dahl S and -R rats,16 with no change in binding parameters in either group on high or low salt chow.17 Hepatic, muscular, and renal insulin receptor mRNA levels were comparable in Dahl S and -R rats fed either low or high salt chow.18 Regarding the impact of salt diet, Dahl S vs. -R rats had significant insulin resistance on high salt diet (8% NaCl) for four weeks vs. normal salt diet.14 Dahl S rats insulin resistance on a high salt diet was characterized by an activation of the early steps in insulin signaling.19 On the other hand, salt retention was significantly greater at weeks 1 and 2 in insulin-infused vs. saline-infused Dahl S rats receiving 0.3% NaCl vs. Dahl R rats, where insulin did not influence sodium retention, mean arterial pressure, or plasma epinephrine.20 In conclusion, genetic background and excessive sodium intake are key factors contributing to the development of insulin resistance and salt sensitive hypertension in Dahl S rats. The decreased sensitivity to insulin in this model may involve a post-receptor defect possibly a genetic variant(s) in the IRS-1 and/or IRS-2 that contribute to their susceptibility to insulin resistance.21,22

Insulin receptor substrates 1 and -2

Variations in candidate genes encoding IRS-1 and -2 proteins involved in the insulin signaling pathway may be implicated in insulin resistance. Insulin actions in skeletal muscles, liver, kidney, fat, and brain result in increased renal sodium retention, modulation of transmembrane cation transport, induction of growth promoting effects of vascular smooth muscle cells, and vascular hyperreactivity.19 The insulin signal transduction pathway is initiated when insulin binds to a high-affinity heterotetrameric transmembrane protein receptor that is present in all mammalian cells.23,24 The insulin-receptor complex then triggers tyrosine phosphorylation of second
messengers, also called docking proteins, such as the insulin receptor substrates-1, 2, 3, and 4 (IRS-1, -2, -3, and -4). This in turn activates the phosphoinositide 3 kinase (PI3K) enzyme, the activation of which stimulates the serine phosphorylation of Akt (Protein kinase B). The latter enzyme (PKB) stimulates glucose transport in muscle and adipose tissue through the translocation of the glucose transporter GLUT4 isofrom to the plasma membrane. AKT also stimulates glycogen synthesis in the liver and muscle, and stimulates lipogenesis in adipose tissue. While IRS-3 and -4 play a role in cell growth and differentiation, IRS-1 and -2 play an important role in glucose metabolism. Genes encoding for IRS-1 and/or -2 therefore may represent attractive candidate genes to study for insulin resistance.

Associations between insulin resistance and common variants in IRS-1 and -2 have been reported in several human populations, including obese Caucasian children and adults, Asian Indians, Mexicans, and African-Americans. Mechanisms underlying the contributions of IRS-1 and IRS-2 variants to insulin resistance include: (i) altered expression and/or function of IRS-1 and/or -2; (ii) diminished IRS-1 and/or -2 binding to the insulin receptor; (iii) hindered binding of IRS-1 and/or -2 variant(s) to the p85 regulatory subunit of the PI3-kinase and a decreased PI3-kinase activity. As a result, a decrease in GLUT4 translocation to the plasma membrane and a reduced glucose transport and glycogen synthesis will ensue. Additionally, an impairment in the ability of IRS-1 and/or -2 to decrease phosphorylation of glycogen synthase kinase-3 (GSK-3), an enzyme that is important in glycogen synthesis, will reduce glycogen synthesis; and (iv) decreased IRS-1 protein levels that are not counterbalanced by a concomitant increase in the IRS-2 protein content. This, in turn, causes a reduction in insulin-stimulated PI3-kinase activity and a significant decrease in Akt phosphorylation and activity. In conclusion, IRS-1 and/or -2 variant(s) appear to contribute to the impaired ability of insulin to activate the IRS/PI3-kinase/Akt/GSK-3 signaling pathway, which ultimately results in defects in glucose transport and glycogen synthesis.

Is it the IRS-1 and/or -2 genetic variations, or the enhanced IRS-1 and/or -2 serine phosphorylation, or both that predispose Dahl S rats to insulin resistance?

IRS-1 and -2 tyrosine phosphorylation activates IRS proteins to bind to signaling molecules in the insulin signaling pathway (such as PI3K). On the other hand, serine phosphorylation of IRS proteins attenuates insulin signaling and explains an additional mechanism of insulin resistance in rodents. For example, increased serine phosphorylation of IRS-1 was demonstrated in the liver of an insulin resistant rat model, supporting the role of serine phosphorylation in precipitating insulin resistance in this model. Owing to the fact that IRS proteins have three times more serine residues than tyrosine residues, the significance of serine phosphorylation has been markedly highlighted. Serine phosphorylation of IRS-1 and IRS-2 can suppress insulin signaling in the following ways: it can (i) allow dissociation of IRS proteins from the insulin receptor; (ii) diminish tyrosine phosphorylation on usual sites by covering up phosphorylation sites and enhancing the release of IRS proteins from intracellular complexes that maintain them in close proximity to the receptor; (iii) enhance IRS proteolytic degradation; or (iv) switch IRS proteins to inhibitors of the insulin receptor.

It is worth mentioning at this point that Dahl S rats have chronic hyperinsulinemia, which potentially might enhance serine phosphorylation of IRS-1 and/or -2 and possibly explain an additional mechanism of insulin resistance in Dahl S rats.

Perspectives

Knowledge of which genetic variants along the insulin signaling pathway are important in the genesis of salt-dependent insulin resistance (a disease that comprises a large subgroup [over 30%] of Canadian adults) would increase the understanding of the basic pathophysiology of the disease. In addition, it may create one or more specific targets for the development of a novel anti-insulin resistance drug or, gene therapy. Variations in genes encoding the IRS-1 or -2 proteins might be at the level of DNA (genetic variants) or at the level of serine phosphorylation as explained above.

References

1. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
2. Kotchen TA, Zhang HY, Covelli M, et al. Insulin resistance and blood pressure in Dahl rats and in one-kidney, one-clip hypertensive rats. Am J Physiol 1991;261:E692-7.
3. Reaven GM, Twerky J, Chang H. Abnormalities of carbohydrate and lipid metabolism in Dahl rats. Hypertension 1991;18:630-5.
4. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
5. Sechi LA, Griffin CA, Zingaro L, et al. Glucose metabolism and insulin receptor binding and mRNA levels in tissues of Dahl hypertensive rats. Am J Hypertens 1997;10:1223-30.
6. Tomiyama H, Kushiro T, Abeta H, et al. Blood pressure responses to hyperinsulinemia in Dahl S rats. Cardiovasc Diabetol 2008;7:19.
7. Scheithauer B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 1995;16:117-42.
8. Laakso M, Malik M, Kekalainen P, et al. Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest 1994;94:1141-6.
IRS-1 defines a unique signal transduction protein. Nature 1991;352:73-7.

22. Sun XJ, Wang LM, Zhang Y, et al. Role of IRS-2 in insulin and cytokine signalling. Nature 1995;377:173-7.

23. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55-62.

24. Tirosli A, Potashnik R, Bashan N, et al. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 1999;274:10595-602.

25. Almind K, Inoue G, Pedersen O, et al. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996;97:2569-75.

26. Berger D, Barroso I, Soos M, et al. Genetic variants of insulin receptor substrate-1 (IRS-1) in syndromes of severe insulin resistance. Functional analysis of Ala513Pro and Gly1158Glu IRS-1. Diabet Med 2002;19:804-9.

27. Celi FS, Negri C, Tanner K, et al. Molecular scanning for mutations in the insulin receptor substrate-1 gene in Mexican Americans with type 2 diabetes mellitus. Diabetes Metab Res Rev 2000;16:370-7.

28. Clausen JO, Hansen T, Bjorbaek C, et al. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 1995;346:397-402.

29. Imai Y, Fusco A, Suzuki Y, et al. Variant sequences of insulin receptor substrate-1 in patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994;79:1655-8.

30. Le Fur S, Le Stunff C, Bougnères P. Increased insulin resistance in obese children who have both 972 IRS-1 and 1057 IRS-2 polymorphisms. Diabetes 2002;51:3304-7.

31. Lei HH, Coresh J, Shuldiner AR, et al. Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 1999;48:1868-72.

32. Mammarella S, Creati B, Esposito DL, et al. Novel allele of the insulin receptor substrate-1 bearing two non-conservative amino acid substitutions in a patient with non-insulin-dependent diabetes mellitus. Mutations in brief no. 130. Online. Hum Mutat 1998:11:411.

33. ’t Hart LM, Nijpels G, Dekker JM, et al. Variations in insulin secretion in carriers of gene variants in IRS-1 and -2. Diabetes 2002;51:884-7.

34. Sesti G, Federici M, Hribal ML, et al. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001;15:2099-111.

35. Qiao LY, Zhane D, Jetten TL, et al. In vivo phosphorylation of insulin receptor substrate-1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem 2002;277:26530-9.

36. Liu YF, Herschkovitz A, Boura-Halfon S, et al. Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate-1 function and promotes insulin resistance. Mol Cell Biol 2004;24:9668-81.

37. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85+: the two sides of a coin. Diabetes 2006;55:2392-7.

38. Greene MW, Sakaue H, Wang L, et al. Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. J Biol Chem 2003;278:8199-211.

39. Paz K, Hemi R, LeRoith D, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997;272:29911-8.